Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer

Status Terminated

Clinical Trial Summary

This phase II trial is studying how well sorafenib works in treating patients with advanced anaplastic thyroid cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Clinical Trial Description

OBJECTIVES:

I. Determine whether the objective response rate is ≥ 20% in patients with advanced anaplastic thyroid cancer treated with sorafenib.

II. Determine the survival of patients treated with this drug. III. Determine the safety profile of this drug in these patients. IV. Determine the pharmacokinetic predictors of response to this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed for survival. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00126568
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Terminated
Phase	Phase 2
Start date	June 2005
Completion date	September 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04420754` - Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer	Phase 1
Completed	`NCT02152137` - Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer	Phase 2
Active, not recruiting	`NCT04552769` - Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer	Phase 2
Active, not recruiting	`NCT04400474` - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study	Phase 2
Completed	`NCT02688608` - Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer	Phase 2
Terminated	`NCT00095693` - Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer	Phase 2
Active, not recruiting	`NCT01240590` - A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)	Phase 1/Phase 2
Not yet recruiting	`NCT05819593` - Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
Active, not recruiting	`NCT04579757` - Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT06374602` - Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer	Phase 2
Recruiting	`NCT06362694` - Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy	Phase 2
Withdrawn	`NCT01701349` - Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer	Phase 3
Active, not recruiting	`NCT03085056` - Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer	Early Phase 1
Recruiting	`NCT01774279` - interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
Completed	`NCT02244463` - A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT05696548` - Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)	Phase 2
Terminated	`NCT00603941` - A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel	Phase 1/Phase 2
Completed	`NCT00280852` - Review of Multimodality Management of Anaplastic Thyroid Cancer	N/A
Recruiting	`NCT04238624` - Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer	Phase 2
Recruiting	`NCT06079333` - NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)	Phase 2